IDKmonitor^® Infliximab Drug Level ELISA Intended Use

The IDKmonitor^® Infliximab Drug Level ELISA is an enzyme immunoassay intended for the quantitative determination of free therapeutic TNFα antibodies infliximab (e.g., REMICADE^®, Remsima^®, Inflectra^®) in EDTA plasma and serum.

In combination with the detection of ADA against infliximab, the IDKmonitor^® Infliximab Drug Level ELISA can help physicians monitor and optimize therapy early on.

Treating Chronic Inflammatory Diseases with Anti-TNFα Antibodies

Tumor necrosis factor-alpha (TNFα) belongs to the proinflammatory cytokines, which promote and sustain inflammatory reactions. It is produced by macrophages and T cells and plays a central role in acute and chronic inflammations. Consequently, chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis are increasingly being treated with antibodies against TNFa, which directly target the underlying inflammatory processes.

The clinical efficacy of an anti-TNFα therapy usually correlates with the trough level of the therapeutic antibody, meaning the drug level just before the next application of the anti-TNFα antibody. Several factors influence the trough level, including dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA).

Health Canada Licensed.

Browse our other IDKmonitor^® Infliximab ELISAs.